Q-omics provides the consensus-scored ZDHHC11B profile across patient tissues and cancer cell-line models. ZDHHC11B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZDHHC11B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, ZDHHC11B RNA expression shows 17,608 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, BLCA, and GBM as cancer lineages where ZDHHC11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC11B survival associations across molecular data types. ZDHHC11B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC11B RNA expression–survival associations across cancer types. High ZDHHC11B expression shows unfavorable associations in UVM, COAD, UCEC and SKCM, but favorable associations in HNSC and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZDHHC11B RNA expression.
This table summarizes ZDHHC11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC11B shows lower tumor expression in BLCA, THCA, LUAD, BRCA and LUSC and higher tumor expression in KICH. The BLCA box plot shows higher ZDHHC11B RNA expression in normal versus tumor tissue (log2 FC = −2.477, t-test p < 0.001).
This table shows molecular features associated with ZDHHC11B in patient tissues and cancer cell lines. In patient samples, ZDHHC11B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
